JP6474430B2 - Ｐｄｅ１０阻害剤の調製のための方法および中間体 - Google Patents

Ｐｄｅ１０阻害剤の調製のための方法および中間体 Download PDF

Info

Publication number
JP6474430B2
JP6474430B2 JP2016564031A JP2016564031A JP6474430B2 JP 6474430 B2 JP6474430 B2 JP 6474430B2 JP 2016564031 A JP2016564031 A JP 2016564031A JP 2016564031 A JP2016564031 A JP 2016564031A JP 6474430 B2 JP6474430 B2 JP 6474430B2
Authority
JP
Japan
Prior art keywords
metal
compound
formula
acid
item
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016564031A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017513885A (ja
JP2017513885A5 (show.php
Inventor
ニール エス． カッツホール，
ニール エス． カッツホール，
ジェニファー リン ゲージ，
ジェニファー リン ゲージ，
トーマス エル． リトル，
トーマス エル． リトル，
ウェイン ダグラス ルーク，
ウェイン ダグラス ルーク，
エリザベス シー．エー． ブロット，
エリザベス シー．エー． ブロット，
マルコ ジョナス，
マルコ ジョナス，
マイケル ジェイムズ マクダーモット，
マイケル ジェイムズ マクダーモット，
カール イー． ライニキ，
カール イー． ライニキ，
Original Assignee
オメロス コーポレーション
オメロス コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オメロス コーポレーション, オメロス コーポレーション filed Critical オメロス コーポレーション
Publication of JP2017513885A publication Critical patent/JP2017513885A/ja
Publication of JP2017513885A5 publication Critical patent/JP2017513885A5/ja
Application granted granted Critical
Publication of JP6474430B2 publication Critical patent/JP6474430B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/40—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic Table
    • C07F1/02—Lithium compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F19/00—Metal compounds according to more than one of main groups C07F1/00 - C07F17/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F3/00—Compounds containing elements of Groups 2 or 12 of the Periodic Table
    • C07F3/02—Magnesium compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Materials Engineering (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
JP2016564031A 2014-04-28 2015-04-24 Ｐｄｅ１０阻害剤の調製のための方法および中間体 Active JP6474430B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461985400P 2014-04-28 2014-04-28
US61/985,400 2014-04-28
PCT/US2015/027647 WO2015167969A1 (en) 2014-04-28 2015-04-24 Processes and intermediates for the preparation of a pde10 inhibitor

Publications (3)

Publication Number Publication Date
JP2017513885A JP2017513885A (ja) 2017-06-01
JP2017513885A5 JP2017513885A5 (show.php) 2018-06-07
JP6474430B2 true JP6474430B2 (ja) 2019-02-27

Family

ID=54359190

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016564031A Active JP6474430B2 (ja) 2014-04-28 2015-04-24 Ｐｄｅ１０阻害剤の調製のための方法および中間体

Country Status (13)

Country Link
US (2) US9650368B2 (show.php)
EP (1) EP3137462B1 (show.php)
JP (1) JP6474430B2 (show.php)
KR (1) KR102496552B1 (show.php)
CN (1) CN106459026B (show.php)
AU (1) AU2015253464B2 (show.php)
BR (1) BR112016025287B1 (show.php)
CA (1) CA2946756C (show.php)
ES (1) ES2723437T3 (show.php)
IL (1) IL248585B (show.php)
NZ (2) NZ716494A (show.php)
RU (1) RU2718863C2 (show.php)
WO (1) WO2015167969A1 (show.php)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017513913A (ja) * 2014-04-28 2017-06-01 オメロス コーポレーション 光学活性なｐｄｅ１０阻害剤

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX339950B (es) * 2010-03-12 2016-06-20 Omeros Corp Inhibidores de fosfodiesterasa 10 (pde10) y composiciones y metodos relacionados.
JP2018535969A (ja) 2015-11-04 2018-12-06 オメロス コーポレーション Ｐｄｅ１０阻害剤の固体状態形態

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK178590D0 (da) 1990-07-26 1990-07-26 Novo Nordisk As 1,4-disubstituerede piperaziner
PT100905A (pt) 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
ES2192192T3 (es) 1992-12-02 2003-10-01 Pfizer Dieteres de catecol como inhibidores selectivos de pde iv.
DE4323192A1 (de) 1993-07-10 1995-01-12 Basf Ag Verfahren zur Herstellung von Homo- und Copolymerisaten von Alk-1-enen
DE4325846C1 (de) 1993-07-31 1995-01-19 Herberts Gmbh Verwendung von Furan-modifizierten aromatischen Pinakolderivaten als Initiatoren und Furan-modifizierte aromatische Pinakolderivate als solche
DE4343286A1 (de) 1993-12-17 1995-06-22 Hoechst Ag Heteroaromatische Verbindungen und ihre Verwendung in flüssigkristallinen Mischungen
DE4409501A1 (de) 1994-03-19 1995-09-21 Didier Werke Ag Verschleißfutter eines Schachtofens und Stein hierfür
WO1996000218A1 (en) 1994-06-24 1996-01-04 Euro-Celtique, S.A. Compounds for and method of inhibiting phosphodiesterase iv
US5789434A (en) 1994-11-15 1998-08-04 Bayer Corporation Derivatives of substituted 4-biarylbutyric acid as matrix metalloprotease inhibitors
TW424087B (en) 1995-04-06 2001-03-01 Janssen Pharmaceutica Nv 1,3-dihydro-1-(phenylalkenyl)-2H-imidazol-2-one derivatives
TW332201B (en) 1995-04-06 1998-05-21 Janssen Pharmaceutica Nv 1,3-Dihydro-1-(phenylalkyl)-2H-imidazol-2-one derivatives
US6037370A (en) 1995-06-08 2000-03-14 Vertex Pharmaceuticals Incorporated Methods and compositions for stimulating neurite growth
DE69712042T2 (de) 1996-01-22 2002-10-02 Fujisawa Pharmaceutical Co., Ltd. Thiazolylbenzofuranderivate und pharmazeutische zusammensetzungen die sie enthalten
AU4015497A (en) 1996-08-26 1998-03-19 Byk Gulden Lomberg Chemische Fabrik Gmbh Thiazole derivatives useful as selective inhibitors of pde-iv
JPH1087543A (ja) 1996-09-17 1998-04-07 Chisso Corp アルコキシベンゼン誘導体、液晶組成物および液晶表示素子
US6548490B1 (en) 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
WO1999045914A1 (en) 1998-03-13 1999-09-16 Maruho Kabushikikaisha Alkyl amine derivative and local anesthetic agent using the same
GB9807354D0 (en) 1998-04-07 1998-06-03 Glaxo Group Ltd Antiviral compound
SE9804212D0 (sv) 1998-12-04 1998-12-04 Astra Pharma Prod Compounds
HK1043127B (zh) 1999-03-12 2004-12-24 贝林格尔‧英格海姆药物公司 作为消炎剂的化合物
US7141593B1 (en) 1999-06-04 2006-11-28 Abbott Laboratories Pharmaceutical formulations
GB9929552D0 (en) 1999-12-14 2000-02-09 Proteus Molecular Design Compounds
US6933304B2 (en) 2000-06-15 2005-08-23 Pharmacia Corporation Heteroarylalkanoic acids as integrin receptor antagonists
US20030032579A1 (en) 2001-04-20 2003-02-13 Pfizer Inc. Therapeutic use of selective PDE10 inhibitors
PL367091A1 (en) 2001-05-22 2005-02-21 Pfizer Products Inc. Crystal forms of azithromycin
US20050165185A1 (en) * 2002-04-18 2005-07-28 Spivey Alan C. Preparation of a conjugated molecule and materials for use therein
US6821502B2 (en) 2002-06-12 2004-11-23 Chevron U.S.A. Inc. Method of making aluminum-containing zeolite with IFR structure
AU2003254481A1 (en) 2002-07-27 2004-02-16 Astrazeneca Ab Chemical compounds
JP4628789B2 (ja) 2002-10-08 2011-02-09 ザ スクリプス リサーチ インスティテュート 脂肪酸アミド加水分解酵素の阻害剤
JP2006509832A (ja) 2002-10-30 2006-03-23 ニューロ３デー サイクリックヌクレオチドホスホジエステラーゼ阻害剤、その調製及び使用
TW200410921A (en) 2002-11-25 2004-07-01 Hoffmann La Roche Mandelic acid derivatives
JP4464280B2 (ja) 2002-12-06 2010-05-19 興和株式会社 エリスロポエチン産生促進剤
CA2507699A1 (en) 2002-12-20 2004-07-15 Pharmacia Corporation Heteroarylalkanoic acids as integrin receptor antagonists
WO2004071509A1 (ja) 2003-02-12 2004-08-26 Nippon Chemiphar Co., Ltd. オリゴデンドロサイト分化促進剤
AU2004232973A1 (en) 2003-04-18 2004-11-04 Memory Pharmaceuticals Corporation Pyrazole derivatives as phosphodiesterase 4 inhibitors
AR047541A1 (es) 2004-02-13 2006-01-25 Sandoz Ag Fosfato de 5-[[4-[2-metil-2-piridinil-amino-etoxi]fenil]metil]-2,4 tiazolidinadiona (rosiglitazona) y sus formas polimorficas
CN1946703A (zh) 2004-04-20 2007-04-11 特兰斯泰克制药公司 取代的噻唑和嘧啶衍生物作为黑素细胞皮质激素受体调节剂
WO2005110410A2 (en) * 2004-05-14 2005-11-24 Abbott Laboratories Kinase inhibitors as therapeutic agents
US7351833B2 (en) 2004-07-23 2008-04-01 Abbott Laboratories (1S,5S)-3-(5,6-dichloropyridin-3-yl)-3,6-diazabicyclo[3.2.0]heptane benzenesulfonate
US7449486B2 (en) * 2004-10-19 2008-11-11 Array Biopharma Inc. Mitotic kinesin inhibitors and methods of use thereof
US8436176B2 (en) 2004-12-30 2013-05-07 Medicis Pharmaceutical Corporation Process for preparing 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine
RS51385B (sr) 2005-01-07 2011-02-28 Pfizer Products Inc. Heteroaromatična jedinjenja hinolina i njihova upotreba kao pde10 inhibitora
CN101384183B (zh) 2005-02-04 2012-07-04 西诺米克斯公司 包含连接有杂芳基部分的化合物及其作为用于食物组合物的新型鲜味调节剂、促味剂和味觉增强剂的应用
EP1871770A1 (en) 2005-04-22 2008-01-02 Kalypsys, Inc. Ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders
UA91546C2 (uk) 2005-05-03 2010-08-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
MY152185A (en) 2005-06-10 2014-08-29 Novartis Ag Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation
CA2617788A1 (en) 2005-08-04 2007-02-15 Apogee Biotechnology Corporation Sphingosine kinase inhibitors and methods of their use
ES2375841T3 (es) 2005-08-29 2012-03-06 Sanofi-Aventis U.S. Llc Nueva forma cristalina de un derivado de piridazino[4,5-b]indol.
US7642246B2 (en) 2005-09-13 2010-01-05 Sicor Inc. Pure rocuronium bromide
KR101439557B1 (ko) 2005-11-15 2014-09-11 오츠카 세이야쿠 가부시키가이샤 옥사졸 화합물 및 제약 조성물
JP2009521429A (ja) 2005-12-23 2009-06-04 アストラゼネカ・アクチエボラーグ Ｇａｂａ−ｂ受容体モジュレーターとしてのイミダゾール
US20090176829A1 (en) 2006-05-02 2009-07-09 Pfizer Inc Bicyclic heteroaryl compounds as pde10 inhibitors
US20080090834A1 (en) 2006-07-06 2008-04-17 Pfizer Inc Selective azole pde10a inhibitor compounds
CA2662535A1 (en) 2006-09-08 2008-03-13 Ore Pharmaceuticals Inc. Method for reducing or alleviating inflammation in the digestive tract
WO2008039431A2 (en) 2006-09-25 2008-04-03 Ptc Therapeutics, Inc. Crystalline forms of 3-[5-(2-fhjorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid
CN101528212A (zh) 2006-09-28 2009-09-09 默克公司 Hdac抑制剂和可螯合的金属化合物的药物组合物以及金属-hdac抑制剂螯合物
US20090253918A1 (en) 2006-10-02 2009-10-08 Janssen Pharmaceuticals, N.V. Novel intermediate for glyt1 inhibitor
US7837978B2 (en) 2006-10-13 2010-11-23 Chevron U.S.A. Inc. Process for preparing aluminum-containing molecular sieve SSZ-26
US7786139B2 (en) * 2006-11-21 2010-08-31 Omeros Corporation PDE10 inhibitors and related compositions and methods
WO2008064342A2 (en) * 2006-11-21 2008-05-29 Omeros Corporation Pde10 inhibitors and related compositions and methods
PE20081506A1 (es) 2006-12-12 2008-12-09 Infinity Discovery Inc Formulaciones de ansamicina
WO2009008906A2 (en) 2007-02-06 2009-01-15 The Trustees Of The University Of Pennsylvania Therapeutic compounds for blocking dna synthesis of pox viruses
EP2160394A1 (en) 2007-05-22 2010-03-10 Ultimorphix Technologies B.v. Tenofovir disoproxil hemi-fumaric acid co-crystal
EP2017264A1 (de) 2007-07-16 2009-01-21 Bayer Cropscience Ag Substituierte Phenylpropargylverbindungen, Verfahren zu deren Herstellung und deren Verwendung als Herbizide und Pflanzenwachstumsregulatoren
US20090186014A1 (en) 2007-10-10 2009-07-23 Ore Pharmaceuticals Inc. Method for treatment of pancreatitis
TW200944520A (en) 2008-01-29 2009-11-01 Glaxo Group Ltd Spiro compounds as NPY Y5 receptor antagonists
WO2009143178A2 (en) 2008-05-20 2009-11-26 Omeros Corporation Pde10 inhibitors and related compositions and methods
TWI501965B (zh) 2008-06-20 2015-10-01 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之新穎苯基咪唑衍生物
US8377930B2 (en) 2008-08-05 2013-02-19 Omeros Corporation PDE10 inhibitors and related compositions and methods
MX339950B (es) * 2010-03-12 2016-06-20 Omeros Corp Inhibidores de fosfodiesterasa 10 (pde10) y composiciones y metodos relacionados.
NZ630803A (en) * 2014-04-28 2016-03-31 Omeros Corp Optically active pde10 inhibitor

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017513913A (ja) * 2014-04-28 2017-06-01 オメロス コーポレーション 光学活性なｐｄｅ１０阻害剤

Also Published As

Publication number Publication date
US9650368B2 (en) 2017-05-16
WO2015167969A1 (en) 2015-11-05
US20180057484A1 (en) 2018-03-01
EP3137462B1 (en) 2019-01-30
US20160024069A1 (en) 2016-01-28
RU2016146118A3 (show.php) 2018-12-24
ES2723437T3 (es) 2019-08-27
IL248585A0 (en) 2016-12-29
EP3137462A4 (en) 2017-12-27
CN106459026A (zh) 2017-02-22
NZ630810A (en) 2016-03-31
CA2946756C (en) 2022-03-29
BR112016025287B1 (pt) 2022-10-11
RU2016146118A (ru) 2018-05-30
BR112016025287A2 (pt) 2017-08-15
AU2015253464A1 (en) 2016-10-27
KR102496552B1 (ko) 2023-02-06
KR20160147275A (ko) 2016-12-22
NZ716494A (en) 2017-07-28
EP3137462A1 (en) 2017-03-08
AU2015253464B2 (en) 2018-11-22
CN106459026B (zh) 2019-07-05
RU2718863C2 (ru) 2020-04-15
IL248585B (en) 2020-03-31
CA2946756A1 (en) 2015-11-05
JP2017513885A (ja) 2017-06-01

Similar Documents

Publication Publication Date Title
JPWO2009096202A1 (ja) ハロ多環芳香族化合物及びその製造方法
WO2012026931A1 (en) Method of synthesizing substituted 2-alkyl phenols
CA3108974A1 (en) Processes for the preparation of (s)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable forms thereof
JP6474430B2 (ja) Ｐｄｅ１０阻害剤の調製のための方法および中間体
AU2021209727A1 (en) Isoindoline derivative, and pharmaceutical composition and use thereof
JP2017513913A (ja) 光学活性なｐｄｅ１０阻害剤
JP2023502123A (ja) Ｓ１ｐ１モジュレーター化合物及び化合物を調製する方法
Khazaei et al. Efficient preparation of some new 1-carbamato-alkyl-2-naphthols using N-halo reagents in neutral media
CN102515996B (zh) 一种合成β-芳基丙烯酰胺类化合物的方法
JP2016204364A (ja) エポキシ化合物の製造方法
JP6067700B2 (ja) アルコール酸化触媒及びそれを用いたアルコール酸化方法
WO2008155745A2 (en) New process for the manufacture of 1h-imidazo[4,5-c]-quinoline ring systems
Zali-Boeini et al. One-step synthesis of imidazo [1, 2-a] pyridines in water
KR20170080190A (ko) 1,5-쌍극자의 [5+3] 고리화 첨가 반응을 이용한 8원 헤테로 고리 화합물의 제조 방법 및 이에 의해 제조된 8원 헤테로 고리 화합물
KR20160086725A (ko) 우수한 안정성을 가지는 아조메틴 일라이드 제조방법 및 다성분 [5+2] 고리화 첨가반응을 통한 1,4-다이아제핀 유도체 제조방법
WO2001030771A1 (en) Thiazolidinedione derivatives
CN121378316A (zh) 一种苯并硼唑7位丙酰胺衍生物及其制备方法和医药用途
KR100902236B1 (ko) 펜에틸 벤조에이트 유도체 및 그의 제조방법
JP2020158500A (ja) １，３，４−オキサ（チア）ジアゾール−２−アミン誘導体の製造法
JP5773308B2 (ja) 光応答性触媒
HK1215436A1 (zh) 取代的(r)-3-(4-甲基氨基甲酰基-3-氟苯基氨基)四氫呋喃-3-甲酸(變體)和其酯，其製備方法和用途
CN101318978A (zh) 一种己内磷酰胺酯类化合物的合成方法
JP2014523917A5 (show.php)
EP2170871A2 (en) Processes for preparing benzimidazole thiophenes
JP2006342110A (ja) トリアジン化合物の製造方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180423

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180423

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20181213

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190115

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190129

R150 Certificate of patent or registration of utility model

Ref document number: 6474430

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250